Repository logo
  • Log In
    New user? Click here to register.Have you forgotten your password?
University College Dublin
    Colleges & Schools
    Statistics
    All of DSpace
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Institutes and Centres
  3. Systems Biology Ireland
  4. SBI Research Collection
  5. Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma
 
  • Details
Options

Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma

Author(s)
Duffy, David J.  
Krstic, Aleksandar  
Halasz, Melinda  
Schwarzl, Thomas  
Fey, Dirk  
Mehta, Jai Prakash  
Killick, Kate  
Turriziani, Benedetta  
Higgins, Desmond G  
Kolch, Walter  
et al.  
Uri
http://hdl.handle.net/10197/9780
Date Issued
2015-12-11
Date Available
2019-04-03T08:15:26Z
Abstract
Despite intensive study, many mysteries remain about the MYCN oncogene's functions. Here we focus on MYCN's role in neuroblastoma, the most common extracranial childhood cancer. MYCN gene amplification occurs in 20% of cases, but other recurrent somatic mutations are rare. This scarcity of tractable targets has hampered efforts to develop new therapeutic options. We employed a multi-level omics approach to examine MYCN functioning and identify novel therapeutic targets for this largely un-druggable oncogene. We used systems medicine based computational network reconstruction and analysis to integrate a range of omic techniques: sequencing-based transcriptomics, genome-wide chromatin immunoprecipitation, siRNA screening and interaction proteomics, revealing that MYCN controls highly connected networks, with MYCN primarily supressing the activity of network components. MYCN's oncogenic functions are likely independent of its classical heterodimerisation partner, MAX. In particular, MYCN controls its own protein interaction network by transcriptionally regulating its binding partners.Our network-based approach identified vulnerable therapeutically targetable nodes that function as critical regulators or effectors of MYCN in neuroblastoma. These were validated by siRNA knockdown screens, functional studies and patient data. We identified β-estradiol and MAPK/ERK as having functional cross-talk with MYCN and being novel targetable vulnerabilities of MYCN-amplified neuroblastoma. These results reveal surprising differences between the functioning of endogenous, overexpressed and amplified MYCN, and rationalise how different MYCN dosages can orchestrate cell fate decisions and cancerous outcomes. Importantly, this work describes a systems-level approach to systematically uncovering network based vulnerabilities and therapeutic targets for multifactorial diseases by integrating disparate omic data types.
Sponsorship
European Commission - Seventh Framework Programme (FP7)
Science Foundation Ireland
Type of Material
Journal Article
Publisher
Impact Journals
Journal
Oncotarget
Volume
6
Issue
41
Start Page
43182
End Page
43201
Copyright (Published Version)
2015 the Authors
Subjects

MYC (c-MYC)

Neuroblastoma

Transcriptional regul...

mRNA sequencing (mRNA...

4sU-seq

DOI
10.18632/oncotarget.6568
Language
English
Status of Item
Peer reviewed
This item is made available under a Creative Commons License
https://creativecommons.org/licenses/by-nc-nd/3.0/ie/
File(s)
Loading...
Thumbnail Image
Name

Integrative omics reveals MYCN as a global suppressor.pdf

Size

7.95 MB

Format

Adobe PDF

Checksum (MD5)

bcd2ec1a43e83fa926f65ae42c24a7f3

Owning collection
SBI Research Collection
Mapped collections
Conway Institute Research Collection•
Medicine Research Collection

Item descriptive metadata is released under a CC-0 (public domain) license: https://creativecommons.org/public-domain/cc0/.
All other content is subject to copyright.

For all queries please contact research.repository@ucd.ie.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement